Odyssey Therapeutics (ODTX) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($815.2 million vs $791.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ODTX | PRME |
|---|---|---|
| Share price | $16.96 | $3.55 |
| Market cap | $815.23M | $791.62M |
| 1-day change | -7.52% | -7.55% |
| YTD return | — | +2.31% |
| 1-year return | — | -2.20% |
| EPS (TTM) | $-6.33 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.63M |
| Revenue growth (YoY) | — | +55.28% |
| Net income (latest FY) | — | $-201.14M |
| Operating margin | — | -4498.06% |
| Net margin | — | -4342.44% |
| 52-week high | $29.05 | $5.91 |
| 52-week low | $15.10 | $2.67 |
| Distance from 52-week high | -41.62% | -39.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +104.42% | +108.17% |
| Average volume | 329.31K | 4.64M |
| Shares outstanding | 48.07M | 222.99M |
| Employees | 100 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
ODTX vs PRME FAQ
Which is bigger, Odyssey Therapeutics or Prime Medicine?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $815.23M compared with $791.62M for Prime Medicine (PRME).
Are Odyssey Therapeutics and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.